MedImmune to Present 10 Abstracts on Influenza at 44th National Immunization Conference

ATLANTA, April 19 /PRNewswire/ -- MedImmune announced today it will present 10 abstracts at the National Immunization Conference (NIC), all of which add to the company's growing body of research regarding pediatric infectious disease prevention.

"With the growing importance of influenza prevention, it is essential to better understand the current data on influenza vaccines as well as how best to provide them to children and adults in the United States," said Alexander A. Zukiwski, M.D., executive vice president and chief medical officer. "The data being presented at the conference build on our extensive foundation of research and help advance innovative solutions for preventing illnesses that negatively impact the health of the U.S. population."

MedImmune abstracts to be presented at NIC on influenza include:

  • "Parent's Decision-Making for Immunizing Children Against Seasonal Influenza."

Flood, E.M., et al. Workshop in the Regency Ballroom VI: April 21, 2010 Time: 11:20AM.

  • "Pediatric Office Characteristics and Activities Associated with Increased Influenza Vaccine Delivery."

Bhatt, P., et al. Workshop in the Centennial Ballroom I: April 22, 2010 Time: 9:20AM.

  • "Relative Efficacy of Live Attenuated and Inactivated Influenza Vaccine in Children as a Function of Time Post Vaccination."

Belshe, R.B., et al. Poster Session in the Grand Hall: April 20-21, 2010 Time: 10 AM4 PM.

  • "Preferences for Influenza Vaccines for Children: Do Children and Parents Agree?"

Rousculp, M.D., et al. Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM4 PM.

  • "High Inter-Office Variability in Pediatric Influenza Vaccination."

Block, S.L., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM4 PM.

  • "Case Reports on Maternal and Fetal Outcomes After Exposure to LAIV During Pregnancy."

Toback, S.L., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM4 PM.

  • "Elementary School-Based Influenza Vaccination Programs: Findings to Inform Pandemic Vaccination Campaigns."

Rousculp, M.D., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM4 PM.

  • "What do Children Know About Influenza and Influenza Vaccines?"

Ryan, K.J., et al. Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM4 PM.

  • "Real-Time Assessment of 2009-2010 Influenza Vaccine Utilization Among Practicing Pediatricians."

Carr, W., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM4 PM.

  • "Live Attenuated Influenza Vaccine and Reduction in Influenza-Associated Acute Otitis Media in Children 24-83 Months."

Block, S.L., et al.  Poster Session in the Grand Hall: April 20-21, 2010 Time: 10AM4 PM.

Additional information about the 44th National Immunization Conference can be found at http://www.cdc.gov/vaccines/events/nic/default.htm.

About MedImmune, Inc.

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, MedImmune aims to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

SOURCE MedImmune

Suggested Articles

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.

The appointments are part of Verona’s efforts to prepare for phase 3 development of ensifentrine in chronic obstructive pulmonary disease.

Syntimmune has had a roller-coaster few years, losing CEOs, gaining new ones and then being snapped up by Alexion in 2018 for up to $1.2 billion.